Development of auto-antibodies towards ß2-glycoprotein I in the antiphospholipid syndrome van Os, G.M.A.
|
|
- Phillip Lester
- 5 years ago
- Views:
Transcription
1 UvA-DARE (Digital Academic Repository) Development of auto-antibodies towards ß2-glycoprotein I in the antiphospholipid syndrome van Os, G.M.A. Link to publication Citation for published version (APA): van Os, G. M. A. (2011). Development of auto-antibodies towards ß2-glycoprotein I in the antiphospholipid syndrome General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam ( Download date: 13 Oct 2018
2 Chapter 1 Current insights into laboratory diagnosis and pathophysiology of the antiphospholipid syndrome Gwen M.A. van Os, Rolf T. Urbanus, Çetin Ağar, Joost C.M. Meijers, Philip G. de Groot Hamostaseologie. 2010; 30 (3):
3 gwen m.a. van os 10 Introduction The antiphospholipid syndrome (APS) is a non-inflammatory autoimmune disease characterized by the presence of antiphospholipid antibodies (apl) in the plasma of patients with venous and/or arterial thrombosis and/or recurrent complications of pregnancy 1,2. The presence of apl in plasma of patients can be detected by either a prolongation of phospholipid dependent coagulation test (lupus anticoagulant, LAC), or by solid phase immune assays against the protein β 2 -glycoprotein I (β 2 GPI) or the phospholipid cardiolipin (anti-β 2 GPI antibody ELISA and anti-cardiolipin antibody ELISA, respectively) 3. For a long time there was a lot of confusion on who had the syndrome and who not. To solve this dispute, an international consensus meeting was organized in Sapporo in 1999 to formulate classification criteria for patients with the antiphospholipid syndrome 4. These criteria have been updated in 2004 at another international consensus meeting in Sydney 5. The classification criteria were defined for scientific purposes and were aimed to be used as inclusion criteria in patient related studies. They were not defined for diagnostic purposes. The actual practice is that these criteria are now used as a diagnostic tool. This is very unfortunate because the specificity of the different apl assays to detect the clinical manifestations that characterize APS are disputable and one of the aims of defining the criteria was the validation as biomarker of the different assays used to detect the presence of thrombosis and pregnancy morbidity. The progress made recently on this important topic will be discussed in the next chapter. Laboratory diagnostics APS is an exceptional syndrome because the clinical symptoms such as thrombosis occur relatively often but are in most cases not due to the presence of antiphospholipid antibodies. As a consequence, the detection of the presence of apl in plasma of a patient with thrombosis or complications of pregnancy is the essential step to define the syndrome. apl is a generic term that describes a collection of closely related but not identical antibodies: LAC activity, anti-cardiolipin antibodies (acl) or anti-β 2 GPI antibodies 6. The fact that the three assays do not measure the same population of antibodies immediately raises two fundamental questions: what are the differences between the different types of antibodies detected with the three assays and which of these three assays is the most relevant one. Meta analyses, case-control cohort studies and prospective studies on the predictive value of the different types of apl have shown that the antibodies that induce LAC activity correlate by far the best with a history of thrombo-embolic complications Apparently, an assay that measures a functional activity, inhibition of a clotting reaction, better predicts a thrombotic risk than assays that measure the presence of a heterogeneous population of auto-antibodies that comprise both those that influence a functional activity and those that do not. Another possible reason why the ELISAs developed to detect the presence of
4 pathophysiology of the antiphospholipid syndrome anti-cardiolipin or anti-β 2 GPI antibodies perform so badly in these association studies is that they are poorly standardized A plasma sample that scored positive in one laboratory can score negative in another. Even between laboratories with extensive experience in the detection of apl antibodies, discordant findings with samples with low titre antibodies are more a rule than an exception. Reliable detection of low titre acl and anti-β 2 GPI antibodies is not possible until now. Based on these observations, a number of researchers including one of us, expressed serious doubts whether the acl ELISA, as it is performed today with the available commercial kits, is specific enough to detect the antiphospholipid syndrome chapter 1 From 1990 on it is known that a subpopulation of acl is directed against β 2 GPI and there are many indications that the anti-β 2 GPI antibodies are in fact the pathological antibodies. However, anti-β 2 GPI antibodies are also a heterogeneous group of antibodies. Antibodies were found directed against all five domains of the protein. A number of studies from different laboratories have suggested that antibodies directed against an epitope around amino acids Arg39 and Arg43 within domain I of β 2 GPI correlates best with the observed clinical manifestation of APS Moreover, addition of isolated domain I to plasma of mice inhibits thrombus formation in a murine model of the antiphospholipid syndrome 18. Apparently, antibodies directed against domain I of β 2 GPI are more relevant antibodies to measure than antibodies against whole β 2 GPI, although we cannot exclude that besides antibodies against domain I other pathological subpopulations of auto-antibodies circulate in blood of APS patients. From the studies published so far it is evident that LAC is the assay of choice to measure clinically relevant apl. However, patients that are not only positive for LAC but also positive for anti-β 2 GPI antibodies have a higher risk for recurrent thrombosis than patients positive in only one assay 19. This is not really a surprise because LAC can not only be caused by antibodies directed against β 2 GPI but also by antibodies against prothrombin 20. There is consensus that the anti-prothrombin antibodies are passive bystanders in the syndrome 5, however, not everybody agrees on this point 21. Nevertheless, the combination LAC and anti-β 2 GPI antibodies identify those anti-β 2 GPI antibodies that are able to induce LAC, a subpopulation of apl that is thought to be responsible for the pathophysiology of APS. In the next paragraph we will discuss how these antibodies could induce a deregulation of the hemostatic balance. Pathophysiology Initially it was thought that apl were directed against anionic phospholipids. We now know that the antibodies are directed against the glycoprotein β 2 GPI bound to anionic
5 gwen m.a. van os 12 surfaces 22,23. β 2 GPI is a plasma protein with no obvious function and persons or mice lacking this protein seem to be completely healthy 24,25. However, animal studies have produced ample evidence that the presence of anti-β 2 GPI antibodies increased thrombus formation after the introduction of a vascular injury 26,27. Also, the presence of anti-β 2 GPI antibodies results in pregnancy loss in a mice model 28. Clearly, the antibodies are gain-of-function antibodies that induce an additional function in β 2 GPI that is responsible for the increased thrombotic risk. β 2 GPI seems to be the playmaker of the antiphospholipid syndrome. β 2 GPI is a glycoprotein with a molecular weight of approximately 45 kda 29. It is present in high concentration in plasma (about 200 mg/ml, 3 mm). Although mrna of β 2 GPI has been found in endothelial cells, astrocytes, neurons and in the extravillous cytotrophoblast and syncytiotrophoblast of the placenta, its major site of synthesis is the liver 30. Originally it was thought that a part of β 2 GPI in the circulation was associated with lipoproteins and, as a consequence, β 2 GPI is also known under the pseudonym apolipoprotein H. Recent evidence, however, showed that the term apolipoprotein H is a misnomer and that β 2 GPI is not associated with lipoprotein fractions 31. β 2 GPI consists of 5 short consensus repeats or sushi domains, domains that are present in many proteins that function in the complement system. The structure of these conserved domains revealed a common globular fold stabilised by two disulfide bridges. The fifth domain is an exception as it has a 6 amino acid residues insertion and a 19 residue C-terminal extension and a third disulphide bridge which includes a cysteine present at the C-terminal end of the protein. The extra amino acids are responsible for the formation of a large positive patch within domain V that forms the binding site for anionic phospholipids. In the middle of this positive loop there is a flexible hydrophobic loop with a classic Trp-Lys motive, often observed in proteins at the site of insertion into cellular membranes 32. LAC and anti-β 2 GPI antibodies are exceptional biomarkers for thrombotic complications because they are correlated with an increased risk for both venous- and arterial thrombosis 1-3. In general, risk markers related to coagulation factors result in venous thrombosis while risk markers related to platelets correlate with arterial thrombosis. We cannot exclude that the risk for arterial thrombosis and the risk of venous thrombosis are the consequence of two separate actions of the β 2 GPI/antibody complexes. However, the observations that β 2 GPI after interaction with its auto-antibodies can bind and activate different cells, have strongly fueled the idea that the cause of the observed thrombotic and pregnancy complications is the deregulation of different cells involved in the maintenance of the hemostatic balance 33. The antibody/β 2 GPI complex has been reported to bind to several cell types, amongst others endothelial cells, monocytes and platelets, all of which play an important
6 pathophysiology of the antiphospholipid syndrome role in hemostasis. The list of potential binding sites on cells for the β 2 GPI/antibody complex is ever increasing and includes annexin A2, LRP8 (low density lipoprotein receptor protein 8 = apolipoprotein E receptor 2 ), glycoprotein Ibα (GPIbα), low density lipoprotein receptor related protein (LRP), megalin, toll-like receptor 2 (TLR2), toll-like receptor 4 (TLR4), the very low density lipoprotein (VLDL) receptor and PSGL-1 (for an overview see reference 2). Most of these receptors are expressed on a number of cell types at various levels in different combinations. The role of these receptors in the activation of different cell types has been studied by several groups with conflicting results. Based on in-vivo experiments with a mouse model for APS, all these receptors seems to be involved in the anti-β 2 GPI antibody-induced thrombotic complications 34-37, which seems very unlikely. Our group has identified LRP8 (ApoER2 ) as the signaling receptor for anti-β 2 GPI antibody/β 2 GPI complexes on platelets and endothelial cells, both in in-vitro studies and in-vivo studies 38. Moreover, we have shown that thrombus formation in a mouse model of APS can be inhibited with a recombinant fragment of LRP8 and thrombus formation was strongly reduced when anti-β 2 GPI antibodies were injected in LRP8 null mice (submitted). Additionally, we have shown that β 2 GPI/anti-β 2 GPI antibody complexes can bind with high affinity to purified LRP8 39. Altogether we propose that LRP8 is an important player in the pathophysiology of APS but we cannot exclude a role of other receptors for β 2 GPI. 13 chapter 1 Future directions No physician or researcher can state that our current knowledge of APS is adequate enough for proper diagnosis and treatment. There are a number of important questions begging for an answer. The knowledge on APS that we have gathered till now strongly suggests that the secret of APS is hidden in the remarkable molecular and cell biology of the protein β 2 GPI. We need to know what the critical elements are in the recognition of β 2 GPI by the anti-β 2 GPI antibodies. Is domain I the only relevant epitope? Why is β 2 GPI only recognized when it is bound to an anionic surface? What is the physiological function of this abundantly present plasma protein? Why do we so often find auto-antibodies against this specific plasma protein? Is β 2 GPI the only playmaker of the syndrome or are there also other plasma proteins and auto-antibodies involved? We have to identify the receptors on the cells responsible for antibody/β 2 GPI complex interaction, and answer the question which cell (platelets, endothelial cells, trophoblasts, monocytes, or others) is the major target for the complexes. Besides thrombosis and fetal loss, many patients suffer from additional clinical manifestations also observed in other microangiopathies, such as thrombocytopenia and hemolysis. Is there a connection? The list of questions is large. We need to answer these questions in the laboratory and confirm the answers in large patient-related studies.
7 gwen m.a. van os 14 AIM OF THIS THESIS There are major indiscrepancies in our understanding of the antiphospholipid syndrome (APS). This autoimmune disease is diagnosed when a patient suffers from thrombosis or pregnancy morbidity and has persistent circulating antiphospholipid antibodies. Despite its name the antibodies are not directed towards phospholipids rather to phospholipid binding proteins. The antiphospholipid antibodies are a heterogeneous group and have many antigens. In the early nineties the dominant antigen was identified as β 2 GPI. Despite this major breakthrough the understanding and treatment of APS did not alter. This thesis aims to gain a better understanding of the etiology and function of antibodies towards β 2 GPI. To achieve this first the different conformations of β 2 GPI was studied (Chapter 2). The observed conformational switch provided insight in a mechanism for which anti-β 2 GPI antibodies arise. In chapter 3 we study etiology of the autoantibodies towards β 2 GPI. Furthermore, the apparent paradox of patients with the antiphospholipid syndrome who have a prolonged coagulation time although they are at higher risk for thrombotic complications was examined in chapter 4. For chapter 5 we did not study the anti-β 2 GPI antibodies in disease but β 2 GPI itself and its role in thrombotic thrombocytopenic purpura. Last the effect of new medication on plasmas positive for anti-β 2 GPI antibodies was studied (Chapter 6). In chapter 7 the implications of the findings described in this thesis are connected and discussed in a broader context.
8 pathophysiology of the antiphospholipid syndrome References Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost. 2003; 1: Urbanus R, Derksen R, de Groot P. Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Rev. 2008; 22: Giannakopoulos B, Passam F, Ioannou Y, Krilis S. How we diagnose the antiphospholipid syndrome. Blood. 2009; 113: Wilson W, Gharavi A, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999; 42: Miyakis S, Lockshin M, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4: Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003; 101: Wahl D, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998; 7: Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999; 25: Ginsberg J, Wells P, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995; 86: Urbanus R, Siegerink B, Roest M, Rosendaal F, de Groot P, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009; 8: Reber G, Boehlen F, de Moerloose P Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream? Semin Thromb Hemost. 2008; 34: Reber G, Arvieux J, Comby E et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d Etudes sur l Hemostase et la Thrombose). Thromb Haemost. 1995; 73: Jennings I, Greaves M, Mackie I, Kitchen S, Woods T, Preston F. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol. 2002; 119: Galli M, Reber G, de Moerloose P, de Groot P. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemostas. 2008; 6: Iverson G, Reddel S, Victoria E, Cockerill K, Wang Y, Marti-Renom M, Sali A, Marquis D, Krilis S, Linnik M. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol. 2002; 169: De Laat B, Derksen R, Urbanus R, de Groot P. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of {beta}2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood. 2005; 105: Ioannou Y, Pericleous C, Giles I, Latchman D, Isenberg D, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum. 2007; 56: Ioannou Y, Romay-Penabad Z, Pericleous C et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost. 2009; 7: Pengo V, Ruffatti A, Legnani C et al. Clinical course of high risk patients diagnosed with Antiphospholipid Syndrome (APS). J Thromb Haemost. 2009; 8: chapter 1
9 gwen m.a. van os Simmelink M, Derksen R, Arnout J, de Groot P. A simple method to discriminate between ß 2 -glycoprotein I and prothrombin-dependent lupus anticoagulants. J Thromb Haemostas. 2003; 1: Oku K, Atsumi T, Amengual O, Koike T. Antiprothrombin antibody testing: detection and clinical utility. Semin Thromb Hemost. 2008; 34: McNeil H, Simpson R, Chesterman C, Krilis S. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: ß 2 glycoprotein I. Proc Natl Acad Sci USA. 1990; 87: Galli M, Comfurius P, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet. 1990; 335: Hoeg J, Segal P, Gregg R et al. Characterization of plasma lipids and lipoproteins in patients with beta 2-glycoprotein I (apolipoprotein H) deficiency. The fasting plasma lipids, lipoproteins, and apolipoproteins were evaluated in 5 subjects. Atherosclerosis. 1985; 55: Sheng Y, Reddel S, Herzog H, Wang Y, Brighton T, France M, Robertson S, Krilis S. Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem. 2001; 276: Jankowski M, Vreys I, Wittevrongel C, Boon D, Vermylen J, Hoylaerts M, Arnout J. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood. 2003; 101: Shoenfeld Y, Blank M, Sherer Y. Induction and treatment of the antiphospholipid syndrome--lessons from animal models. Eur J Clin Invest. 2001;31: Girardi G, Redecha P, Salmon J. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004; 10: Lozier J, Takahashi N, Putnam F. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci U S A. 1984; 81: Ragusa M, Costa S, Cefalù A, Noto D, Fayer F, Travali S, Averna M, Gianguzza F. RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues. Int J Mol Med. 2006; 18: Ağar C, de Groot P, Levels J, Marquart J, Meijers J. Beta-Glycoprotein I is incorrectly named apolipoprotein H. J Thromb Haemostas. 2009; 7: Bouma B, de Groot P, van der Elsen J, Ravelli R, Schouten A, Simmelink M, Derksen R, Kroon J, Gros P. Adhesion mechanism of human ß 2 -glycoprotein I to phospholipids based on its crystal structure. EMBO J. 1999; 18: Palomo I, Segovia F, Ortega C, Pierangeli S. Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease. Clin Exp Rheumatol. 2009; 27: Satta N, Dunoyer-Geindre S, Reber G, Fish R, Boehlen F, Kruithof E, de Moerloose P. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood. 2007; 109: Pierangeli S, Vega-Ostertag M, Raschi E et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis. 2007; 66: Romay-Penabad Z, Liu X, Montiel-Manzano G, Papalardo De Martínez E, Pierangeli S. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann N Y Acad Sci. 2007; 1108: Romay-Penabad Z, Montiel-Manzano M, Shilagard T et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood. 2009; 114: Lutters B, Derksen R, Tekelenburg W, Lenting P, Arnout J, de Groot P. Dimers of ß 2 -glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2. J Biol Chem. 2003; 278: Pennings M, Derksen R, Urbanus R, Tekelenburg W, Hemrika W, de Groot P. Platelets express three different splice variants of ApoER2 that are all involved in signaling. J Thromb Haemostas. 2007; 5:
Thyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A.
UvA-DARE (Digital Academic Repository) Thyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A. Link to publication Citation for published version (APA): Squizzato, A.
More informationWarfarin Does Not Interfere with Lupus Anticoagulant Detection by Dilute Russell s Viper Venom Time
Clin. Lab. 2009;55:XXX-XXX Copyright ORIGINAL ARTICLE Warfarin Does Not Interfere with Lupus Anticoagulant Detection by Dilute Russell s Viper Venom Time HORATIU OLTEANU 2, KATHARINE. A. DOWNES 1, JIGAR
More informationAnti β 2. -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome
Coagulation and Transfusion Medicine / PREDICTIVE VALUE OF ANTIPHOSPHOLIPID ANTIBODIES Anti β -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With
More informationManifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria
Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Farjah H AlGahtani Associate professor,md,mph Leukemia,Lymphoma in adolescent,thromboembolic
More informationAntiphospholipid Syndrome ( APS)
Antiphospholipid Syndrome ( APS) Edward John Walter Bowie, MD Mayo Medical School the first to identify APS as an acquired thrombophilia Graham Robert Vivian Hughes MD FRCP Unit Rayne Institute St Thomas
More informationKey words: antiphospholipid syndrome, trombosis, pathogenesis
26. XI,. 4/2011,.,..,..,., -..,,. 2GPI. -,.,,., -,, -, -,,,,, IL-1, IL-2, IL-6, IL-8, IL-12, IL-10, TNF, INF-. :,, N. Stoilov, R. Rashkov and R. Stoilov. ANTIPHOSPHOLIPID SYNDROME HISTORICAL DATA, ETI-
More informationUvA-DARE (Digital Academic Repository) Marfan syndrome: Getting to the root of the problem Franken, Romy. Link to publication
UvA-DARE (Digital Academic Repository) Marfan syndrome: Getting to the root of the problem Franken, Romy Link to publication Citation for published version (APA): Franken, R. (2016). Marfan syndrome: Getting
More informationUvA-DARE (Digital Academic Repository) Improving aspects of palliative care for children Jagt, C.T. Link to publication
UvA-DARE (Digital Academic Repository) Improving aspects of palliative care for children Jagt, C.T. Link to publication Citation for published version (APA): Jagt, C. T. (2017). Improving aspects of palliative
More informationThrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS
Autoimmune Thrombophilia Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Saraf@sina.tums.ac.ir Acquired Thrombophilia HIT PNH Cyckle cell Anemia Myeloproliferative lf Diseases Thrombocytosis
More informationPathophysiology of antiphospholipid antibodies
Pathophysiology of antiphospholipid antibodies P.G. de Groot 1*, R.H.W.M. Derksen 2 1 Department of Haematology, Room G03.647, 2 Department of Rheumatology and Clinical Immunology, University Medical Centre
More informationCurrent View of the Treatment of Antiphospholipid Syndrome
GROUPE HOSPITALIER PITIE SALPETRIERE Current View of the Treatment of Antiphospholipid Syndrome Pr Zahir AMOURA Department of Internal Medicine French National Reference center for SLE and APS Hôpital
More informationCitation for published version (APA): van Munster, B. C. (2009). Pathophysiological studies in delirium : a focus on genetics.
UvA-DARE (Digital Academic Repository) Pathophysiological studies in delirium : a focus on genetics van Munster, B.C. Link to publication Citation for published version (APA): van Munster, B. C. (2009).
More informationUvA-DARE (Digital Academic Repository) Vascular factors in dementia and apathy Eurelings, Lisa. Link to publication
UvA-DARE (Digital Academic Repository) Vascular factors in dementia and apathy Eurelings, Lisa Link to publication Citation for published version (APA): Eurelings, L. S. M. (2016). Vascular factors in
More informationCitation for published version (APA): Sivapalaratnam, S. (2012). The molecular basis of early onset cardiovascular disease
UvA-DARE (Digital Academic Repository) The molecular basis of early onset cardiovascular disease Sivapalaratnam, S. Link to publication Citation for published version (APA): Sivapalaratnam, S. (2012).
More informationChapter 2 Natural Proteins Involved in Antiphospholipid Syndrome
Chapter 2 Natural Proteins Involved in Antiphospholipid Syndrome Philip G. de Groot, Bas de Laat, Jacob Rand, Panayiotis G. Vlachoyiannopoulos, Fatima El-Assaad, Steven A. Krilis, and Bill Giannakopoulos
More informationAntiphospholipid Antibody Testing: Which Are Most Useful for Diagnosis?
Rheum Dis Clin N Am 32 (2006) 455 463 Antiphospholipid Antibody Testing: Which Are Most Useful for Diagnosis? Maria Laura Bertolaccini, MD, PhD*, Graham R.V. Hughes, MD, FRCP Lupus Research Unit, The Rayne
More informationORIGINAL PAPERS. Marek Cieśla 1, B D, Ewa Wypasek 1, 2, B D 1, 2, A, E, F. Abstract
ORIGINAL PAPERS Adv Clin Exp Med 2014, 23, 5, 729 733 ISSN 1899 5276 Copyright by Wroclaw Medical University Marek Cieśla 1, B D, Ewa Wypasek 1, 2, B D 1, 2, A, E, F, Anetta Undas IgA Antiphospholipid
More informationArterial thrombosis in the antiphospholipid syndrome. Rolf T. Urbanus
Arterial thrombosis in the antiphospholipid syndrome Rolf T. Urbanus ISBN / EAN: 978-90-393-4943-4 Cover art: White willow on a field of endothelial cells and a sky filled with preactivated platelets by
More informationUvA-DARE (Digital Academic Repository) An electronic nose in respiratory disease Dragonieri, S. Link to publication
UvA-DARE (Digital Academic Repository) An electronic nose in respiratory disease Dragonieri, S. Link to publication Citation for published version (APA): Dragonieri, S. (2012). An electronic nose in respiratory
More informationTitle. CitationLupus, 21(14): Issue Date Doc URL. Rights. Type. File Information
Title Predominant prevalence of arterial thrombosis in Jap Fujieda, Yuichiro; Atsumi, Tatsuya; Amengual, Olga; Author(s) Yujiro; Horita, Tetsuya; Yasuda, Shinsuke; Koike, Ta CitationLupus, 21(14): 1506-1514
More informationUvA-DARE (Digital Academic Repository) The artificial pancreas Kropff, J. Link to publication
UvA-DARE (Digital Academic Repository) The artificial pancreas Kropff, J. Link to publication Citation for published version (APA): Kropff, J. (2017). The artificial pancreas: From logic to life General
More informationPrediction of toxicity in concurrent chemoradiation for non-small cell lung cancer Uijterlinde, W.I.
UvA-DARE (Digital Academic Repository) Prediction of toxicity in concurrent chemoradiation for non-small cell lung cancer Uijterlinde, W.I. Link to publication Citation for published version (APA): Uijterlinde,
More informationThe significance of autoantibodies against 2 -glycoprotein I
Review article The significance of autoantibodies against 2 -glycoprotein I Philip G. de Groot 1 and Rolf T. Urbanus 1 1 Department of Clinical Chemistry and Haematology, University Medical Center, Utrecht,
More informationCitation for published version (APA): Oderkerk, A. E. (1999). De preliminaire fase van het rechtsvergelijkend onderzoek Nijmegen: Ars Aequi Libri
UvA-DARE (Digital Academic Repository) De preliminaire fase van het rechtsvergelijkend onderzoek Oderkerk, A.E. Link to publication Citation for published version (APA): Oderkerk, A. E. (1999). De preliminaire
More informationClinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B.
UvA-DARE (Digital Academic Repository) Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B. Link to publication Citation for published version (APA): Post, B. (2009). Clinimetrics,
More informationAntiphospholipid Syndrome
Antiphospholipid Syndrome EliA Cardiolipin and EliA β2-glycoprotein I Fully Automated Testing for Antiphospholipid Syndrome (APS) Testing for APS according to classification criteria determination of anti-β2-glycoprotein
More informationUvA-DARE (Digital Academic Repository) Marfan syndrome: Getting to the root of the problem Franken, Romy. Link to publication
UvA-DARE (Digital Academic Repository) Marfan syndrome: Getting to the root of the problem Franken, Romy Link to publication Citation for published version (APA): Franken, R. (2016). Marfan syndrome: Getting
More informationTHROMBOPHILIA SCREENING
THROMBOPHILIA SCREENING Introduction The regulation of haemostasis Normally, when a clot occurs, it exactly occurs where it has to be and does not grow more than necessary due to the action of the haemostasis
More informationUvA-DARE (Digital Academic Repository)
UvA-DARE (Digital Academic Repository) Clinical studies and tissue analyses in the earliest phases of rheumatoid arthritis: In search of the transition from being at risk to having clinically apparent
More informationUvA-DARE (Digital Academic Repository) Genetic basis of hypertrophic cardiomyopathy Bos, J.M. Link to publication
UvA-DARE (Digital Academic Repository) Genetic basis of hypertrophic cardiomyopathy Bos, J.M. Link to publication Citation for published version (APA): Bos, J. M. (2010). Genetic basis of hypertrophic
More informationCitation for published version (APA): Wijkerslooth de Weerdesteyn, T. R. (2013). Population screening for colorectal cancer by colonoscopy
UvA-DARE (Digital Academic Repository) Population screening for colorectal cancer by colonoscopy de Wijkerslooth, T.R. Link to publication Citation for published version (APA): Wijkerslooth de Weerdesteyn,
More informationPrevalence of antiphospholipid auto antibodies in patients with thrombosis
EUROPEAN ACADEMIC RESEARCH Vol. IV, Issue 6/ September 2016 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Prevalence of antiphospholipid auto antibodies in patients
More informationGezinskenmerken: De constructie van de Vragenlijst Gezinskenmerken (VGK) Klijn, W.J.L.
UvA-DARE (Digital Academic Repository) Gezinskenmerken: De constructie van de Vragenlijst Gezinskenmerken (VGK) Klijn, W.J.L. Link to publication Citation for published version (APA): Klijn, W. J. L. (2013).
More informationBacterial meningitis in adults: Host and pathogen factors, treatment and outcome Heckenberg, S.G.B.
UvA-DARE (Digital Academic Repository) Bacterial meningitis in adults: Host and pathogen factors, treatment and outcome Heckenberg, S.G.B. Link to publication Citation for published version (APA): Heckenberg,
More informationSummary of the 11th International Congress on Antiphospholipid Antibodies, Sydney, Australia, November 2004
Journal of Reproductive Immunology 66 (2005) 85 90 Meeting report Summary of the 11th International Congress on Antiphospholipid Antibodies, Sydney, Australia, November 2004 The 11th International Congress
More informationKeywords: apl, Hughes syndrome, pregnancy loss, prothrombin, thrombosis. Introduction
Journal of Thrombosis and Haemostasis, 10: 2512 2518 DOI: 10.1111/jth.12014 ORIGINAL ARTICLE Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of
More informationAnxiety disorders in children with autism spectrum disorders: A clinical and health care economic perspective van Steensel, F.J.A.
UvA-DARE (Digital Academic Repository) Anxiety disorders in children with autism spectrum disorders: A clinical and health care economic perspective van Steensel, F.J.A. Link to publication Citation for
More informationAntiphospholipid antibodies in patients with venous thrombosis at Kenyatta National Hospital
Research article Department of Human Pathology, School of Medicine, University of Nairobi, P. O. Box 19676 00202, Nairobi, Kenya Corresponding author: Dr KA Barasa, Department of Human Pathology, School
More informationUvA-DARE (Digital Academic Repository) The systemic right ventricle van der Bom, T. Link to publication
UvA-DARE (Digital Academic Repository) The systemic right ventricle van der Bom, T. Link to publication Citation for published version (APA): van der Bom, T. (2014). The systemic right ventricle. General
More informationSang Hyuk Park, 1,2 Seongsoo Jang, 3 Chan-Jeoung Park, 3 and Hyun-Sook Chi Introduction
BioMed Research International Volume 2016, Article ID 2641526, 6 pages http://dx.doi.org/10.1155/2016/2641526 Research Article Clinical Application of Revised Laboratory Classification Criteria for Antiphospholipid
More informationCitation for published version (APA): Parigger, E. M. (2012). Language and executive functioning in children with ADHD Den Bosch: Boxpress
UvA-DARE (Digital Academic Repository) Language and executive functioning in children with ADHD Parigger, E.M. Link to publication Citation for published version (APA): Parigger, E. M. (2012). Language
More informationThe Antiphospholipid Syndrome
The Antiphospholipid Syndrome 1 / 6 2 / 6 3 / 6 The Antiphospholipid Syndrome Antiphospholipid antibody syndrome (commonly called antiphospholipid syndrome or APS) is an autoimmune disease present mostly
More informationCharacterizing scaphoid nonunion deformity using 2-D and 3-D imaging techniques ten Berg, P.W.L.
UvA-DARE (Digital Academic Repository) Characterizing scaphoid nonunion deformity using 2-D and 3-D imaging techniques ten Berg, P.W.L. Link to publication Citation for published version (APA): ten Berg,
More informationClinical consequences of antiphospholipid antibodies
Clinical consequences of antiphospholipid antibodies R.H.W.M. Derksen 1*, P.G. de Groot 2,3 1 Department of Rheumatology and Clinical Immunology, Room F02.127, 2 Thrombosis and Haemostasis Laboratory,
More informationAdvances in Abdominal Aortic Aneurysm Care - Towards personalized, centralized and endovascular care van Beek, S.C.
UvA-DARE (Digital Academic Repository) Advances in Abdominal Aortic Aneurysm Care - Towards personalized, centralized and endovascular care van Beek, S.C. Link to publication Citation for published version
More informationCitation for published version (APA): Von Eije, K. J. (2009). RNAi based gene therapy for HIV-1, from bench to bedside
UvA-DARE (Digital Academic Repository) RNAi based gene therapy for HIV-1, from bench to bedside Von Eije, K.J. Link to publication Citation for published version (APA): Von Eije, K. J. (2009). RNAi based
More informationUvA-DARE (Digital Academic Repository) Genetic variation in Helicobacter pylori Pan, Z. Link to publication
UvA-DARE (Digital Academic Repository) Genetic variation in Helicobacter pylori Pan, Z. Link to publication Citation for published version (APA): Pan, Z. (1999). Genetic variation in Helicobacter pylori
More informationDual-therapy stent technology for patients with coronary artery disease Kalkman, D.N.
UvA-DARE (Digital Academic Repository) Dual-therapy stent technology for patients with coronary artery disease Kalkman, D.N. Link to publication Citation for published version (APA): Kalkman, D. N. (2018).
More informationUvA-DARE (Digital Academic Repository) Tick-host-pathogen interactions in Lyme borreliosis Hovius, J.W.R. Link to publication
UvA-DARE (Digital Academic Repository) Tick-host-pathogen interactions in Lyme borreliosis Hovius, J.W.R. Link to publication Citation for published version (APA): Hovius, J. W. R. (2009). Tick-host-pathogen
More informationEnzyme replacement therapy in Fabry disease, towards individualized treatment Arends, M.
UvA-DARE (Digital Academic Repository) Enzyme replacement therapy in Fabry disease, towards individualized treatment Arends, M. Link to publication Citation for published version (APA): Arends, M. (2017).
More informationThrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE
LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion:
More informationEvaluation of antiphospholipid antibodies testing for the diagnosis of antiphospholipid syndrome
Original Article Evaluation of antiphospholipid antibodies testing for the diagnosis of antiphospholipid syndrome Paula Gonçalves Perches¹, Daniela Pezzutti Domingues¹, Andréia Latanza Gomes², Augusta
More informationAMORE (Ablative surgery, MOulage technique brachytherapy and REconstruction) for childhood head and neck rhabdomyosarcoma Buwalda, J.
UvA-DARE (Digital Academic Repository) AMORE (Ablative surgery, MOulage technique brachytherapy and REconstruction) for childhood head and neck rhabdomyosarcoma Buwalda, J. Link to publication Citation
More informationUvA-DARE (Digital Academic Repository)
UvA-DARE (Digital Academic Repository) Standaarden voor kerndoelen basisonderwijs : de ontwikkeling van standaarden voor kerndoelen basisonderwijs op basis van resultaten uit peilingsonderzoek van der
More informationUvA-DARE (Digital Academic Repository) Intraarterial treatment for acute ischemic stroke Berkhemer, O.A. Link to publication
UvA-DARE (Digital Academic Repository) Intraarterial treatment for acute ischemic stroke Berkhemer, O.A. Link to publication Citation for published version (APA): Berkhemer, O. A. (2016). Intraarterial
More informationBooks MDPI. Antiphospholipid Antibodies and Syndrome. antibodies. Edited by Ricard Cervera
antibodies Antiphospholipid Antibodies and Syndrome www.mdpi.com/journal/antibodies Edited by Ricard Cervera Printed Edition of the Special Issue Published in Antibodies Antiphospholipid Antibodies and
More informationPathophysiological insights into the antiphospholipid syndrome
State of the art 202 Pathophysiological insights into the antiphospholipid syndrome Karl J. Lackner 1,2 ; Davit Manukyan 1,2,3 ; Nadine Müller-Calleja 1,2,3 1 Institute of Clinical Chemistry and Laboratory
More informationLaboratory methods to detect antiphospholipid antibodies
NONTRADITIONAL LABORATORY ASSAYS OF HEMOSTASIS:WHAT THE CONSULTING HEMATOLOGIST SHOULD KNOW Laboratory methods to detect antiphospholipid antibodies Steven A. Krilis 1,3 and Bill Giannakopoulos 1,2,3 1
More informationDiagnostic research in perspective: examples of retrieval, synthesis and analysis Bachmann, L.M.
UvA-DARE (Digital Academic Repository) Diagnostic research in perspective: examples of retrieval, synthesis and analysis Bachmann, L.M. Link to publication Citation for published version (APA): Bachmann,
More informationUvA-DARE (Digital Academic Repository) Cancer, thrombosis and low-molecular-weight heparins Piccioli, A. Link to publication
UvA-DARE (Digital Academic Repository) Cancer, thrombosis and low-molecular-weight heparins Piccioli, A. Link to publication Citation for published version (APA): Piccioli, A. (2015). Cancer, thrombosis
More informationFecal Microbiota Transplantation: Clinical and experimental studies van Nood, E.
UvA-DARE (Digital Academic Repository) Fecal Microbiota Transplantation: Clinical and experimental studies van Nood, E. Link to publication Citation for published version (APA): van Nood, E. (2015). Fecal
More informationCitation for published version (APA): van Es, N. (2017). Cancer and thrombosis: Improvements in strategies for prediction, diagnosis, and treatment
UvA-DARE (Digital Academic Repository) Cancer and thrombosis van Es, N. Link to publication Citation for published version (APA): van Es, N. (2017). Cancer and thrombosis: Improvements in strategies for
More informationIdentifying and evaluating patterns of prescription opioid use and associated risks in Ontario, Canada Gomes, T.
UvA-DARE (Digital Academic Repository) Identifying and evaluating patterns of prescription opioid use and associated risks in Ontario, Canada Gomes, T. Link to publication Citation for published version
More informationUvA-DARE (Digital Academic Repository) Falling: should one blame the heart? Jansen, Sofie. Link to publication
UvA-DARE (Digital Academic Repository) Falling: should one blame the heart? Jansen, Sofie Link to publication Citation for published version (APA): Jansen, S. (2015). Falling: should one blame the heart?
More informationBuilding blocks for return to work after sick leave due to depression de Vries, Gabe
UvA-DARE (Digital Academic Repository) Building blocks for return to work after sick leave due to depression de Vries, Gabe Link to publication Citation for published version (APA): de Vries, G. (2016).
More informationPhospholipid Screen IgG/IgM ELISA Kit
Phospholipid Screen IgG/IgM ELISA Kit Catalog Number KA1109 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationUvA-DARE (Digital Academic Repository) What tumor cells cannot resist Ebbing, E.A. Link to publication
UvA-DARE (Digital Academic Repository) What tumor cells cannot resist Ebbing, E.A. Link to publication Citation for published version (APA): Ebbing, E. A. (2018). What tumor cells cannot resist: Mechanisms
More informationStudies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R.
UvA-DARE (Digital Academic Repository) Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R. Link to publication Citation for published version
More informationPURPOSE SCIENTIFIC QUESTIONS. How the prevalence of the nine different apl varies among the different age groups of patients with SLE?
Project plan The prevalence of IgG, IgM, and IgA antibodies against cardiolipin, β2-glycoprotein I and domain I of β2-glycoprotein I in a large cohort of patients with Systemic Lupus Erythematosus and
More informationAntiphospholipid antibodies are a heterogeneous family
Seasonal Distribution of Antiphospholipid Antibodies Thanh-Ha Luong, MD; Jacob H. Rand, MD; Xiao-Xuan Wu, MD; James H. Godbold, PhD; Mayra Gascon-Lema, MS; Stanley Tuhrim, MD Background and Purpose The
More informationCitation for published version (APA): Zeddies, S. (2015). Novel regulators of megakaryopoiesis: The road less traveled by
UvA-DARE (Digital Academic Repository) Novel regulators of megakaryopoiesis: The road less traveled by Zeddies, S. Link to publication Citation for published version (APA): Zeddies, S. (2015). Novel regulators
More informationLupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines
Journal of Thrombosis and Haemostasis, 9: 1776 1783 DOI: 10.1111/j.1538-7836.2011.04420.x ORIGINAL ARTICLE Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines J.
More informationGenerate Knowledge Lupus Anticoagulant Testing Made Simple
Generate Knowledge Lupus Anticoagulant Testing Made Simple Paul Riley, PhD, MBA Learning objectives Describe antiphospholipid syndrome (aps) and role of the lupus anticoagulant (LA) in thrombosis Present
More informationMohammadreza Tabatabaei IBTO COAG LAB
Tests for the Evaluation of Lupus Anticoagulants t Mohammadreza Tabatabaei MSc Hematology blood bank MSc Hematology blood bank IBTO COAG LAB Lupus Anticoagulants General Background Lupus anticoagulants
More informationThe antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?
Autoimmun Highlights (2010) 1:5 14 DOI 10.1007/s13317-010-0003-7 REVIEW ARTICLE The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours? Emmanuel
More informationCitation for published version (APA): Bartels, S. A. L. (2013). Laparoscopic colorectal surgery: beyond the short-term effects
UvA-DARE (Digital Academic Repository) Laparoscopic colorectal surgery: beyond the short-term effects Bartels, S.A.L. Link to publication Citation for published version (APA): Bartels, S. A. L. (2013).
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Presence of Antiphospholipid Antibodies as a Risk Factor for Thrombotic Events in Patients with Connective Tissue Diseases and Idiopathic Thrombocytopenic Purpura Koji Habe 1,HideoWada
More informationT he antiphospholipid syndrome (APS) is a thrombophilic
1639 EXTENDED REPORT ntiphospholipid antibody tests: spreading the net M L ertolaccini, S Gomez, J F P Pareja, Theodoridou, G Sanna, G R V Hughes, M Khamashta... See end of article for authors affiliations...
More informationUvA-DARE (Digital Academic Repository) Innovative therapies and new targets in psoriasis de Groot, M. Link to publication
UvA-DARE (Digital Academic Repository) Innovative therapies and new targets in psoriasis de Groot, M. Link to publication Citation for published version (APA): de Groot, M. (2011). Innovative therapies
More informationAvailable Online at CODEN: IJRSFP (USA) Vol. 9, Issue, 3(L), pp , March, 2018.
ISSN: 0976-3031 Available Online at http://www.recentscientific.com CODEN: IJRSFP (USA) International Journal of Recent Scientific Research Vol. 9, Issue, 3(L), pp. 25504-25508, March, 2018 Research Article
More informationUvA-DARE (Digital Academic Repository) Mucorales between food and infection Dolat Abadi, S. Link to publication
UvA-DARE (Digital Academic Repository) Mucorales between food and infection Dolat Abadi, S. Link to publication Citation for published version (APA): Dolatabadi, S. (2015). Mucorales between food and infection
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationCitation for published version (APA): Donker, M. (2014). Improvements in locoregional treatment of breast cancer
UvA-DARE (Digital Academic Repository) Improvements in locoregional treatment of breast cancer Donker, Mila Link to publication Citation for published version (APA): Donker, M. (2014). Improvements in
More informationUvA-DARE (Digital Academic Repository) Workplace coaching: Processes and effects Theeboom, T. Link to publication
UvA-DARE (Digital Academic Repository) Workplace coaching: Processes and effects Theeboom, T. Link to publication Citation for published version (APA): Theeboom, T. (2016). Workplace coaching: Processes
More informationUvA-DARE (Digital Academic Repository) Malaria during pregnancy in Rwanda Rulisa, S. Link to publication
UvA-DARE (Digital Academic Repository) Malaria during pregnancy in Rwanda Rulisa, S. Link to publication Citation for published version (APA): Rulisa, S. (2014). Malaria during pregnancy in Rwanda General
More informationThe role of media entertainment in children s and adolescents ADHD-related behaviors: A reason for concern? Nikkelen, S.W.C.
UvA-DARE (Digital Academic Repository) The role of media entertainment in children s and adolescents ADHD-related behaviors: A reason for concern? Nikkelen, S.W.C. Link to publication Citation for published
More informationThe antiphospholipid syndrome: still an enigma
CHALLENGING SCENARIOS IN THROMBOSIS The antiphospholipid syndrome: still an enigma Shruti Chaturvedi 1 and Keith R. McCrae 2 1 Division of Hematology, Vanderbilt University Medical Center, Nashville, TN;
More informationFamilial hypercholesterolemia in childhood: diagnostics, therapeutical options and risk stratification Rodenburg, J.
UvADARE (Digital Academic Repository) Familial hypercholesterolemia in childhood: diagnostics, therapeutical options and risk stratification Rodenburg, J. Link to publication Citation for published version
More informationCitation for published version (APA): Diederen, K. (2018). Pediatric inflammatory bowel disease: Monitoring, nutrition and surgery.
UvA-DARE (Digital Academic Repository) Pediatric inflammatory bowel disease Diederen, K. Link to publication Citation for published version (APA): Diederen, K. (2018). Pediatric inflammatory bowel disease:
More informationCitation for published version (APA): Azaripour, A. (2016). Structure and function of the human periodontium: Science meets the clinician
UvA-DARE (Digital Academic Repository) Structure and function of the human periodontium Azaripour, A. Link to publication Citation for published version (APA): Azaripour, A. (2016). Structure and function
More informationUvA-DARE (Digital Academic Repository) Obesity, ectopic lipids, and insulin resistance ter Horst, K.W. Link to publication
UvA-DARE (Digital Academic Repository) Obesity, ectopic lipids, and insulin resistance ter Horst, K.W. Link to publication Citation for published version (APA): ter Horst, K. W. (2017). Obesity, ectopic
More informationKawasaki disease: Studies on etiology, treatment and long-term follow-up Tacke, C.E.A.
UvA-DARE (Digital Academic Repository) Kawasaki disease: Studies on etiology, treatment and long-term follow-up Tacke, C.E.A. Link to publication Citation for published version (APA): Tacke, C. E. A. (2014).
More informationCitation for published version (APA): Braakhekke, M. W. M. (2017). Randomized controlled trials in reproductive medicine: Disclosing the caveats
UvA-DARE (Digital Academic Repository) Randomized controlled trials in reproductive medicine Braakhekke, M.W.M. Link to publication Citation for published version (APA): Braakhekke, M. W. M. (2017). Randomized
More informationTECHNICAL SERIES. Lupus Anticoagulants: Basic Concepts and Laboratory Diagnosiss. ...Setting trends TULIP DIAGNOSTICS (P) LTD.
For the use of Registered Medical Practioners and Laboratories only TECHNICAL SERIES Lupus Anticoagulants: Basic Concepts and Laboratory Diagnosiss TULIP DIAGNOSTICS (P) LTD. Gitanjali, Tulip Block, Dr.
More informationTobacco control policies and socio-economic inequalities in smoking cessation Bosdriesz, J.R.
UvA-DARE (Digital Academic Repository) Tobacco control policies and socio-economic inequalities in smoking cessation Bosdriesz, J.R. Link to publication Citation for published version (APA): Bosdriesz,
More informationTHROMBOSIS PRODUCT HIGHLIGHTS
PRODUCT HIGHLIGHTS AESKU.DIAGNOSTICS has extensive experience and know-how in the Anti-Phospholipid Syndrome (APS) field and offers the most comprehensive panel of anti-phospholipid tests, employing highly
More informationAntigen Specificity of Antiphospholipid Syndrome-Related Antiphospholipid
The Open Autoimmunity Journal, 2010, 2, 21-27 21 Open Access Antigen Specificity of Antiphospholipid Syndrome-Related Antiphospholipid Antibodies Ricardo Forastiero* Department of Physiology, Favaloro
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationDaniel Egan, MD April 13, 2012
Daniel Egan, MD April 13, 2012 Aug 2006 (at age 15): Acute unprovoked DVT in left common femoral vein Factor V Leiden heterozygous Positive lupus inhibitor Lovenox BID 2 weeks later: increased clot burden,
More informationCitation for published version (APA): Luijendijk, P. (2014). Aortic coarctation: late complications and treatment strategies.
UvA-DARE (Digital Academic Repository) Aortic coarctation: late complications and treatment strategies Luijendijk, P. Link to publication Citation for published version (APA): Luijendijk, P. (2014). Aortic
More information